Long-term efficacy of a protease inhibitor-sparing, nucleoside reverse transcriptase inhibitor-limiting antiretroviral regimen with nevirapine, lamivudine, and reduced standard stavudine dosage.
Shalit
Peter
P
Farrell
Pat
P
McClarty
Mark
M
D000328:Adult; D044966:Anti-Retroviral Agents / Q000378:metabolism* / Q000627:therapeutic use*; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D019829:Nevirapine / Q000494:pharmacology* / Q000627:therapeutic use*; D009705:Nucleosides / Q000378:metabolism*; D011480:Protease Inhibitors / Q000378:metabolism* / Q000627:therapeutic use*; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D018119:Stavudine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D013995:Time
D044966:Anti-Retroviral Agents; D009705:Nucleosides; D011480:Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D019829:Nevirapine; D018119:Stavudine